Loss and revival of androgen receptor signaling in advanced prostate cancer
This 2021 review examines the mechanisms underlying the transition of prostate cancer from androgen receptor (AR)-positive to AR-negative states, a shift associated with poor prognosis. The study highlights that potent AR signaling inhibitors (ARSIs) like enzalutamide and abiraterone, while initially effective, can lead to increased cases of AR-negative prostate cancer
June 26, 2025
No Comments